Overview

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Status:
COMPLETED

Trial end date:
2024-10-17

Target enrollment:

Participant gender:

Summary

This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics (PK), metabolic profile, and safety and tolerability.

Phase:

PHASE1

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Collaborator:

Orion Corporation, Orion Pharma

Treatments:

Fludrocortisone
fludrocortisone acetate
Prednisone